Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Kamran SC, Zhou Y, Otani K, Drumm M, Otani Y, Wu S, Wu CL, Feldman AS, Wszolek M, Lee RJ, Saylor PJ, Lennerz J, Van Allen E, Willers H, Hong TS, Liu Y, Davicioni E, Gibb EA, Shipley WU, Mouw KW, Efstathiou JA, Miyamoto DT. Kamran SC, et al. Among authors: drumm m. Clin Cancer Res. 2023 Dec 15;29(24):5116-5127. doi: 10.1158/1078-0432.CCR-23-0792. Clin Cancer Res. 2023. PMID: 37870965 Free PMC article.
Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. Efstathiou JA, et al. Among authors: drumm mr. Eur Urol. 2019 Jul;76(1):59-68. doi: 10.1016/j.eururo.2019.01.011. Epub 2019 Feb 1. Eur Urol. 2019. PMID: 30712971 Free PMC article.
Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA. Mak KS, et al. Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1028-1036. doi: 10.1016/j.ijrobp.2016.08.023. Epub 2016 Aug 24. Int J Radiat Oncol Biol Phys. 2016. PMID: 27727064
Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Giacalone NJ, et al. Among authors: drumm m. Eur Urol. 2017 Jun;71(6):952-960. doi: 10.1016/j.eururo.2016.12.020. Epub 2017 Jan 9. Eur Urol. 2017. PMID: 28081860
Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer.
Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodríguez D, Feldman AS, Dahl DM, Heney NM, Shipley WU, Zietman AL, Efstathiou JA. Sanchez A, et al. Among authors: drumm m. J Urol. 2018 Feb;199(2):407-415. doi: 10.1016/j.juro.2017.08.106. Epub 2017 Sep 1. J Urol. 2018. PMID: 28870862
Complications and Outcomes of Salvage Cystectomy after Trimodality Therapy.
Pieretti A, Krasnow R, Drumm M, Gusev A, Dahl DM, McGovern F, Blute ML, Shipley WU, Efstathiou JA, Feldman AS, Wszolek MF. Pieretti A, et al. Among authors: drumm m. J Urol. 2021 Jul;206(1):29-36. doi: 10.1097/JU.0000000000001696. Epub 2021 Feb 22. J Urol. 2021. PMID: 33617327
[No title available]
[No authors listed] [No authors listed] PMID: 34700567
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Zlotta AR, et al. Among authors: drumm m. Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12. Lancet Oncol. 2023. PMID: 37187202
PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H. Liu Q, et al. Among authors: drumm m. Oncogene. 2018 May;37(21):2793-2805. doi: 10.1038/s41388-018-0130-6. Epub 2018 Mar 7. Oncogene. 2018. PMID: 29511347 Free PMC article.
180 results